CAPTRUST Financial Advisors
JAZZ icon

CAPTRUST Financial Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

CAPTRUST Financial Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.27M Buy
6,729
+1,728
+35% +$302K ﹤0.01% 1473
2025
Q4 		$850K Buy
5,001
+324
+7% +$49.7K ﹤0.01% 1597
2025
Q3 		$616K Buy
4,677
+62
+1% +$7.44K ﹤0.01% 1687
2025
Q2 		$490K Sell
4,615
-255
-5% -$27.7K ﹤0.01% 1743
2025
Q1 		$605K Sell
4,870
-467
-9% -$60.9K ﹤0.01% 1535
2024
Q4 		$657K Buy
5,337
+372
+7% +$43.8K ﹤0.01% 1463
2024
Q3 		$553K Buy
4,965
+430
+9% +$47.1K ﹤0.01% 1517
2024
Q2 		$484K Sell
4,535
-258
-5% -$28.4K ﹤0.01% 1522
2024
Q1 		$577K Sell
4,793
-522
-10% -$63.9K ﹤0.01% 1417
2023
Q4 		$654K Sell
5,315
-158
-3% -$19.7K ﹤0.01% 1542
2023
Q3 		$708K Sell
5,473
-7,281
-57% -$970K ﹤0.01% 1414
2023
Q2 		$1.58M Buy
12,754
+7,825
+159% +$1.05M 0.01% 932
2023
Q1 		$721K Buy
4,929
+179
+4% +$26.5K ﹤0.01% 1211
2022
Q4 		$757K Sell
4,750
-156
-3% -$22.9K ﹤0.01% 1123
2022
Q3 		$654K Buy
4,906
+1,180
+32% +$179K ﹤0.01% 1119
2022
Q2 		$581K Buy
3,726
+19
+0.5% +$2.92K ﹤0.01% 1081
2022
Q1 		$577K Buy
3,707
+86
+2% +$12.5K ﹤0.01% 1084
2021
Q4 		$461K Buy
3,621
+240
+7% +$31.5K ﹤0.01% 1166
2021
Q3 		$440K Sell
3,381
-107
-3% -$16.2K ﹤0.01% 1097
2021
Q2 		$620K Buy
3,488
+250
+8% +$43.3K 0.01% 910
2021
Q1 		$532K Buy
3,238
+418
+15% +$68.8K 0.01% 935
2020
Q4 		$465K Buy
2,820
+110
+4% +$16.4K 0.01% 861
2020
Q3 		$391K Hold
2,710
– – 0.01% 792
2020
Q2 		$297K Sell
2,710
-605
-18% -$66.9K ﹤0.01% 873
2020
Q1 		$317K Sell
3,315
-525
-14% -$67.9K 0.01% 707
2019
Q4 		$570K Buy
3,840
+3,620
+1,645% +$493K 0.01% 648
2019
Q3 		$28K Hold
220
– – ﹤0.01% 1196
2019
Q2 		$31K Buy
220
+120
+120% +$16.1K ﹤0.01% 1143
2019
Q1 		$14K Sell
100
-14
-12% -$1.83K ﹤0.01% 1293
2018
Q4 		$14K Buy
114
+14
+14% +$2.08K ﹤0.01% 1132
2018
Q3 		$17K Buy
+100
New +$17.2K ﹤0.01% 1066

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

CAPTRUST Financial Advisors's JAZZ Position: Q1 2026 in Review

CAPTRUST Financial Advisors increased its Jazz Pharmaceuticals (JAZZ) stake by 35% in Q1 2026, buying an estimated $302K and bringing the position to 6,729 shares worth $1.27M. The position accounts for ﹤0.01% of the portfolio, ranked #1473.

CAPTRUST Financial Advisors first reported a position in JAZZ in Q3 2018 and has held it in 31 quarters since. The position peaked at $1.58M in Q2 2023. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • CAPTRUST Financial Advisors held 6,729 shares of Jazz Pharmaceuticals worth $1.27M as of Q1 2026.
  • CAPTRUST Financial Advisors bought 1,728 Jazz Pharmaceuticals shares in Q1 2026, an estimated $302K.
  • Jazz Pharmaceuticals made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q1 2026, its #1473 holding.
  • CAPTRUST Financial Advisors first reported a position in Jazz Pharmaceuticals in Q3 2018 and has held it in 31 quarters since.
  • CAPTRUST Financial Advisors's Jazz Pharmaceuticals position peaked at $1.58M in Q2 2023.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.